PE20230513A1 - 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmaceuticas del mismo - Google Patents

2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmaceuticas del mismo

Info

Publication number
PE20230513A1
PE20230513A1 PE2022001806A PE2022001806A PE20230513A1 PE 20230513 A1 PE20230513 A1 PE 20230513A1 PE 2022001806 A PE2022001806 A PE 2022001806A PE 2022001806 A PE2022001806 A PE 2022001806A PE 20230513 A1 PE20230513 A1 PE 20230513A1
Authority
PE
Peru
Prior art keywords
quinazolin
piperazin
methoxyphenyl
trifluoromethyl
fluoro
Prior art date
Application number
PE2022001806A
Other languages
English (en)
Inventor
Helmut Buschmann
Thomas Goldner
Jessica Redmer
Andrea Hawe
Matthias Lucke
Dorothea Hohmann
Monica Rosa
Original Assignee
Aic246 Ag And Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aic246 Ag And Co Kg filed Critical Aic246 Ag And Co Kg
Publication of PE20230513A1 publication Critical patent/PE20230513A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA LIQUIDA QUE COMPRENDE UNA SAL DE SODIO DE LETERMOVIR QUE COMPRENDE AL MENOS UN EXCIPIENTE SELECCIONADO DEL GRUPO QUE CONSISTE EN UN CARBOHIDRATO TAL COMO SACAROSA Y MANITOL, UN AMINOACIDO TAL COMO FENILALANINA, UN COMPUESTO POLIALCOXI TAL COMO UN POLOXAMERO 188 Y UNA POLIVINILPIRROLIDONA (PVP), EN PARTICULAR PVP PF12; EN DONDE LA COMPOSICION TIENE UN PH EN EL INTERVALO DE 7 A 8. TAMBIEN SE REFIERE A UN METODO DE PREPARACION DE LA COMPOSICION. DICHA COMPOSICION DE LA SAL DE SODIO DE LETERMOVIR ES UTIL EN EL TRATAMIENTO DE INFECCIONES POR CITOMEGALOVIRUS HUMANO (HCMV).
PE2022001806A 2020-02-27 2021-03-01 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmaceuticas del mismo PE20230513A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20159699 2020-02-27
PCT/EP2021/055062 WO2021170878A1 (en) 2020-02-27 2021-03-01 Sodium 2-[(4s)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4h-quinazolin-4-yl]acetate and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
PE20230513A1 true PE20230513A1 (es) 2023-03-24

Family

ID=69742703

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001806A PE20230513A1 (es) 2020-02-27 2021-03-01 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmaceuticas del mismo

Country Status (19)

Country Link
US (1) US20230095980A1 (es)
EP (1) EP4110302A1 (es)
JP (1) JP2023520627A (es)
KR (1) KR20220148861A (es)
CN (1) CN115427024A (es)
AR (1) AR122386A1 (es)
AU (1) AU2021228240A1 (es)
BR (1) BR112022016931A2 (es)
CA (1) CA3169084A1 (es)
CL (1) CL2022002292A1 (es)
CO (1) CO2022012032A2 (es)
CU (1) CU20220048A7 (es)
EC (1) ECSP22066676A (es)
IL (1) IL295682A (es)
MX (1) MX2022010443A (es)
PE (1) PE20230513A1 (es)
TW (1) TW202140021A (es)
UY (1) UY39099A (es)
WO (1) WO2021170878A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114942278B (zh) * 2022-04-12 2023-09-08 山东诚创蓝海医药科技有限公司 来特莫韦中间体二d-(+)-二对甲基苯甲酰酒石酸乙酸乙酯络合物有关物质的分析方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319612A1 (de) 2003-05-02 2004-11-18 Bayer Healthcare Ag Substituierte Dihydrochinazoline
DE102012101659A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Salze eines Dihydrochinazolinderivats
DE102012101680A1 (de) 2012-02-29 2013-08-29 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung enthaltend ein antiviral wirksames Dihydrochinazolinderivat
CN109966244A (zh) * 2017-12-27 2019-07-05 天津耀辰实业发展有限公司 一种含有乐特莫韦的药物组合物

Also Published As

Publication number Publication date
JP2023520627A (ja) 2023-05-18
UY39099A (es) 2021-08-31
WO2021170878A1 (en) 2021-09-02
US20230095980A1 (en) 2023-03-30
CO2022012032A2 (es) 2022-11-29
CU20220048A7 (es) 2023-04-10
EP4110302A1 (en) 2023-01-04
BR112022016931A2 (pt) 2022-10-11
AR122386A1 (es) 2022-09-07
KR20220148861A (ko) 2022-11-07
CA3169084A1 (en) 2021-09-02
AU2021228240A1 (en) 2022-10-20
CN115427024A (zh) 2022-12-02
IL295682A (en) 2022-10-01
ECSP22066676A (es) 2022-12-30
TW202140021A (zh) 2021-11-01
CL2022002292A1 (es) 2023-02-03
MX2022010443A (es) 2022-10-18

Similar Documents

Publication Publication Date Title
RU2008138646A (ru) Жидкая композиция g-csf
NO20030533L (no) Vandige farmasöytiske preparater
WO2001002424A3 (en) Peptide boronic acid inhibitors of hepatitis c virus protease
SI3023415T1 (en) Histone demethylase inhibitors
ME00556A (en) Freeze-dried pantoprazole preparation and pantoprazole injection
PE20140734A1 (es) Composicion y formulacion que comprende iduronato-2-sulfatasa humano recombinante y metodo de preparacion de las mismas
AR080072A1 (es) Composicion farmaceutica solida con mejoradores y metodos para prepararla
RU2011153353A (ru) Кетолидные соединения, обладающие противомикробной активностью
PE20230514A1 (es) Composiciones farmaceuticas que comprenden acetato de 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] e iones de sodio
PE20230513A1 (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio y composiciones farmaceuticas del mismo
PE20090618A1 (es) Compuestos para el tratamiento de hepatitis c
EA199800938A1 (ru) Композиции, содержащие антигрибковый агент и ацетатный буфер
MX2023002463A (es) Formulaciones de compuestos antivirales.
ATE404176T1 (de) Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors
CU23318A7 (es) Composiciones farmacã0/00uticas de la tizoxanida y nitazoxanida
JP2018532806A5 (es)
EP4382092A1 (en) Stable liquid formulation containing botulinum toxin
CN101378790A (zh) 用于促进多细胞生物的组织愈合的组合物和方法
EA200801364A1 (ru) Новое производное плевромутилина и его применение
HRP20030907B1 (en) Pharmaceutical composition based on macrolides for topical application in ophthalmology
BR0006301A (pt) Macrólidos antibacterianos e pró-cinéticos
EA199901012A1 (ru) Фармацевтические композиции на основе тизоксанида и нитазоксанида
CO2022012017A2 (es) 2-[(4s)-8-fluoro-2-[4-(3-metoxifenil)piperazin-1-il]-3-[2-metoxi-5-(trifluorometil)fenil]-4h-quinazolin-4-il] acetato de sodio monohidrato, su preparación y uso
RU2016152691A (ru) Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
AR119805A1 (es) Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso